It seems AGC is really looking to expand it biopharmaceutical manufacturing arm.
It recently acquired a bio company for $60 billion Japanese yen.
AGC Signs Agreement for Acquisition of a Leading Biopharmaceutical CDMO, CMC Biologics
"AGC has been engaged in contract manufacturing business since the early 2000s. Its acquisition of CMC is part of AGC’s strategy to expand its biologics CDMO operations, complementing AGC’s current operations in Japan and Europe*note. The business integration with CMC will enable AGC to offer world-leading biologics CDMO API services, with a host of best-in-class technologies and manufacturing solutions by both mammalian and microbial operations for its global customer base.
Under its management policy, AGC plus , the AGC Group has designated its Life Science Business as one of its strategic areas. Through the business integration, the AGC Group will accelerate and expand its biopharmaceutical contract services business around the world."
I guess they have done that further now with Regeneus but they seem to be aggressively perusing this side of their business arm. I wonder what also will happen down the track with RGS and AGC??
RGS Price at posting:
16.5¢ Sentiment: Buy Disclosure: Held
